Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company dedicated to the advent of optical biopsy. The company researches, develops and markets innovative tools to visualize and detect cellular abnormalities during endoscopic procedures. Its flagship product, Cellvizio®, a probe-­based Confocal Laser Endomicroscopy (pCLE) system, provides physicians and researchers high-­resolution cellular views of tissue inside the body. Large, international, multi-center clinical trials have demonstrated Cellvizio's ability to help physicians more accurately detect early forms of disease and make treatment decisions immediately. Designed to improve patient outcomes and reduce costs within a hospital, Cellvizio can be used with almost any endoscope. Cellvizio has 510(k) clearance from the U.S. Food and Drug Administration and the European CE-­‐Mark for use in the GI tract, biliary and pancreatic ducts and lungs.
Type
Public
HQ
Paris, FR
Founded
2000
Size (employees)
83 (est)
Mauna Kea Technologies was founded in 2000 and is headquartered in Paris, FR

Mauna Kea Technologies Office Locations

Mauna Kea Technologies has offices in Paris and Cambridge
Paris, FR (HQ)
9 Rue d'Enghien
Cambridge, US
210 185 Alewife Brook Pkwy

Mauna Kea Technologies Data and Metrics

Mauna Kea Technologies Financial Metrics

EUR

Market capitalization (24-Jul-2017)

45.4 m

Closing share price (24-Jul-2017)

2.3
Mauna Kea Technologies's current market capitalization is €45.4 m.

Mauna Kea Technologies Market Value History

Traffic Overview of Mauna Kea Technologies

Mauna Kea Technologies Online and Social Media Presence

Mauna Kea Technologies Company Life and Culture

You may also be interested in